STIM Neuronetics

Neuronetics Appoints Sara Grubbs as Vice President, Sales

Neuronetics Appoints Sara Grubbs as Vice President, Sales
EN
05/10/2020

Underlying

STIMNeuronetics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Op...

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis versus Q4 2024 Continued cash management improvement, with cash provided by operations of $0.9 million in Q4 2025 Expect full year 2026 revenue of between $160 million and $166 million Dan Reuvers appointed as President and Chief Executive Officer, effective March 23, 2026; pr...

March 17, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Appoints Dan Reuvers as President and Chief Executive Offi...

Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer Seasoned leader brings more than 30 years of medical device experience, with a proven track record of growing revenue, earnings, and cash flow across multiple publicly traded healthcare companies MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today an...

March 17, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Resu...

Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026....

March 3, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter an...

Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with t...

February 10, 2026 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare...

Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference MALVERN, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ: STIM) (the “Company” or “Neuronetics”) a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that the management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, Dec. 4, 2025. T...

November 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch